{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:06:18Z","timestamp":1792800378663,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Clinical Research Services","id":[{"id":"https:\/\/ror.org\/01c127k53","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e.,\u00a0glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02539-2","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T20:03:31Z","timestamp":1665345811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["New strategies to improve clinical outcomes for diabetic kidney disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Thomas","family":"Forst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Streckbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"2539_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas.\u00a0https:\/\/diabetesatlas.org\/2021.\u00a0Accessed 30 Aug\u00a02022."},{"key":"2539_CR2","doi-asserted-by":"publisher","first-page":"k1497","DOI":"10.1136\/bmj.k1497","volume":"362","author":"G Xu","year":"2018","unstructured":"Xu G, Liu B, Sun Y, Du Y, Snetselaar LG, Hu FB, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ. 2018;362:k1497.","journal-title":"BMJ."},{"key":"2539_CR3","unstructured":"World Health Organization. Diabetes Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes. Accessed 30 Aug\u00a02022."},{"key":"2539_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","volume":"12","author":"MC Thomas","year":"2016","unstructured":"Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12:73\u201381.","journal-title":"Nat Rev Nephrol"},{"key":"2539_CR5","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49\u201356.","journal-title":"J Nephropharmacol"},{"key":"2539_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molmet.2019.10.005","volume":"30","author":"H Fu","year":"2019","unstructured":"Fu H, Liu S, Bastacky SI, Wang X, Tian X-J, Zhou D. Diabetic kidney diseases revisited: a new perspective for a new era. Mol Metab. 2019;30:250\u201363.","journal-title":"Mol Metab"},{"key":"2539_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.13355","volume":"3","author":"H Li","year":"2021","unstructured":"Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017. J Diabetes Investig. 2021;3:346\u201356.","journal-title":"J Diabetes Investig"},{"key":"2539_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm9040947","volume":"9","author":"JL G\u00f3rriz","year":"2020","unstructured":"G\u00f3rriz JL, Soler MJ, Navarro-Gonz\u00e1lez JF, Garc\u00eda-Carro C, Puchades MJ, D'Marco L, et al. GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med. 2020;9:947.","journal-title":"J Clin Med"},{"key":"2539_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"2539_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","volume":"25","author":"RZ Alicic","year":"2018","unstructured":"Alicic RZ, Johnson EJ, Tuttle KR. Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. Adv Chronic Kidney Dis. 2018;25:181\u201391.","journal-title":"Adv Chronic Kidney Dis"},{"key":"2539_CR11","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2539_CR12","doi-asserted-by":"publisher","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","volume":"312","author":"R Pichler","year":"2017","unstructured":"Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Ren Physiol. 2017;312:F716\u2013f31.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2539_CR13","doi-asserted-by":"publisher","first-page":"165796","DOI":"10.1016\/j.bbadis.2020.165796","volume":"1866","author":"C Cappelli","year":"2020","unstructured":"Cappelli C, Tellez A, Jara C, Alarc\u00f3n S, Torres A, Mendoza P, et al. The TGF-\u03b2 profibrotic cascade targets ecto-5'-nucleotidase gene in proximal tubule epithelial cells and is a traceable marker of progressive diabetic kidney disease. Biochim Biophys Acta Mol basis Dis. 2020;1866:165796.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"2539_CR14","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1093\/ndt\/gfn379","volume":"23","author":"A Chagnac","year":"2008","unstructured":"Chagnac A, Herman M, Zingerman B, Erman A, Rozen-Zvi B, Hirsh J, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 2008;23:3946\u201352.","journal-title":"Nephrol Dial Transplant"},{"key":"2539_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJMra1808786","volume":"384","author":"T Benzing","year":"2021","unstructured":"Benzing T, Salant D. Insights into glomerular filtration and albuminuria. N Engl J Med. 2021;384:1437\u201346.","journal-title":"N Engl J Med"},{"key":"2539_CR16","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1097\/HJH.0b013e3283495cd6","volume":"29","author":"G Penno","year":"2011","unstructured":"Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011;29:1802\u20139.","journal-title":"J Hypertens"},{"key":"2539_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000333249","volume":"2","author":"JP Dwyer","year":"2012","unstructured":"Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: Results from the DEMAND study. Cardiorenal Med. 2012;2:1\u201310.","journal-title":"Cardiorenal Med"},{"key":"2539_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s40001-021-00612-9","volume":"26","author":"L Deng","year":"2021","unstructured":"Deng L, Li W, Xu G. Update on pathogenesis and diagnosis flow of normoalbuminuric diabetes with renal insufficiency. Eur J Med Res. 2021;26:144.","journal-title":"Eur J Med Res"},{"key":"2539_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TWC Tervaert","year":"2010","unstructured":"Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"2539_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semnephrol.2018.02.002","volume":"38","author":"SH Ballew","year":"2018","unstructured":"Ballew SH, Matsushita K. Cardiovascular risk prediction in ckd. Semin Nephrol. 2018;38:208\u201316.","journal-title":"Semin Nephrol"},{"key":"2539_CR21","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.2337\/dc20-S011","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 11. Microvascular complications and foot care: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S135\u2013s51.","journal-title":"Diabetes Care"},{"key":"2539_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"2539_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1681\/ASN.2006080872","volume":"18","author":"BA Perkins","year":"2007","unstructured":"Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18:1353\u201361.","journal-title":"J Am Soc Nephrol"},{"key":"2539_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","volume":"79","author":"C Delgado","year":"2022","unstructured":"Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, et al. A unifying approach for gfr estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79:268\u201388 e1.","journal-title":"Am J Kidney Dis"},{"key":"2539_CR25","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMe2114918","volume":"385","author":"WW Williams","year":"2021","unstructured":"Williams WW, Hogan JW, Ingelfinger JR. Time to eliminate health care disparities in the estimation of kidney function. N Engl J Med. 2021;385:1804\u20136.","journal-title":"N Engl J Med"},{"key":"2539_CR26","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin c-based equations to estimate gfr without race. N Engl J Med. 2021;385:1737\u201349.","journal-title":"N Engl J Med"},{"key":"2539_CR27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1\u2013s115.","journal-title":"Kidney Int"},{"key":"2539_CR28","doi-asserted-by":"publisher","first-page":"e2148940","DOI":"10.1001\/jamanetworkopen.2021.48940","volume":"5","author":"DC Chen","year":"2022","unstructured":"Chen DC, Shlipak MG, Scherzer R, Bauer SR, Potok OA, Rifkin DE, et al. Association of intraindividual difference in estimated glomerular filtration rate by creatinine vs cystatin c and end-stage kidney disease and mortality. JAMA Netw Open. 2022;5:e2148940.","journal-title":"JAMA Netw Open"},{"key":"2539_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1373\/clinchem.2016.264325","volume":"63","author":"A-S Bargnoux","year":"2017","unstructured":"Bargnoux A-S, Pi\u00e9roni L, Cristol J-P, Kuster N, Delanaye P, Carlier M-C, et al. Multicenter evaluation of cystatin c measurement after assay standardization. Clin Chem. 2017;63:833\u201341.","journal-title":"Clin Chem"},{"key":"2539_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.2010.39","volume":"303","author":"BR Hemmelgarn","year":"2010","unstructured":"Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423\u20139.","journal-title":"JAMA."},{"key":"2539_CR31","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073\u201381.","journal-title":"Lancet."},{"key":"2539_CR32","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.2337\/dc20-S006","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S66\u2013s76.","journal-title":"Diabetes Care"},{"key":"2539_CR33","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2215\/CJN.11111016","volume":"12","author":"SM Doshi","year":"2017","unstructured":"Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12:1366\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2539_CR34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Kidney Disease Improving Global Outcomes Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1\u2013s87.","journal-title":"Kidney Int"},{"key":"2539_CR35","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc21-S010","volume":"44","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142021. Diabetes Care. 2020;44:S125\u2013S50.","journal-title":"Diabetes Care"},{"key":"2539_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/kisup.2013.27","volume":"3","author":"Kidney Disease Improving Global Outcomes Lipid Work Group","year":"2013","unstructured":"Kidney Disease Improving Global Outcomes Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:259\u2013305.","journal-title":"Kidney Int Suppl"},{"key":"2539_CR37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703\u201313.","journal-title":"BMJ"},{"key":"2539_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","volume":"15","author":"M Foretz","year":"2019","unstructured":"Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15:569\u201389.","journal-title":"Nat Rev Endocrinol"},{"key":"2539_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1568026620666191224141617","volume":"20","author":"W Lv","year":"2020","unstructured":"Lv W, Wang X, Xu Q, Lu W. Mechanisms and characteristics of sulfonylureas and glinides. Curr Top Med Chem. 2020;20:37\u201356.","journal-title":"Curr Top Med Chem"},{"key":"2539_CR40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2539_CR41","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2539_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131\u20138.","journal-title":"Lancet."},{"key":"2539_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2539_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"2539_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1475-2840-13-102","volume":"13","author":"B Zinman","year":"2014","unstructured":"Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME\u2122). Cardiovasc Diabetol. 2014;13:102.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR46","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:2099.","journal-title":"N Engl J Med"},{"key":"2539_CR47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"2539_CR48","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425\u201335.","journal-title":"N Engl J Med"},{"key":"2539_CR49","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2539_CR50","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1331\/JAPhA.2009.09078","volume":"49","author":"JJ Neumiller","year":"2009","unstructured":"Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003). 2009;49(Suppl 1):S16\u201329.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2539_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839\u201348.","journal-title":"N Engl J Med"},{"key":"2539_CR52","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519\u201329.","journal-title":"Lancet."},{"key":"2539_CR53","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"2539_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","volume":"18","author":"LE Clegg","year":"2019","unstructured":"Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019;18:138.","journal-title":"Cardiovasc Diabetol"},{"key":"2539_CR55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021;17:227\u201344.","journal-title":"Nat Rev Nephrol"},{"key":"2539_CR56","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2539_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"2539_CR58","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"issue":"6","key":"2539_CR59","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316(6):602\u201310.","journal-title":"JAMA."},{"key":"2539_CR60","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896\u2013907.","journal-title":"N Engl J Med"},{"key":"2539_CR61","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","volume":"23","author":"NA Thornberry","year":"2009","unstructured":"Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23:479\u201386.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2539_CR62","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","volume":"63","author":"M Diamant","year":"2003","unstructured":"Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003;63:1373\u2013405.","journal-title":"Drugs."},{"key":"2539_CR63","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u201353.","journal-title":"Lancet."},{"key":"2539_CR64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kint.2016.05.002","volume":"90","author":"CM Wyatt","year":"2016","unstructured":"Wyatt CM, Cattran DC. Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes? Kidney Int. 2016;90:8\u201310.","journal-title":"Kidney Int"},{"key":"2539_CR65","volume-title":"A Reseach Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW)","author":"U.S. National Library of Medicine","year":"2022","unstructured":"U.S. National Library of Medicine. A Reseach Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW) 2022 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819153:ClinicalTirals.gov."},{"key":"2539_CR66","volume-title":"A research study to find out how semaglutide works in the kidneys compared to placebo, in people with type 2 diabetes and chronic kidney disease (the REMODEL trial)","author":"U.S. National Library of Medicine","year":"2022","unstructured":"U.S. National Library of Medicine. A research study to find out how semaglutide works in the kidneys compared to placebo, in people with type 2 diabetes and chronic kidney disease (the REMODEL trial) 2022 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT048657702022."},{"key":"2539_CR67","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2539_CR68","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2539_CR69","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129\u201339.","journal-title":"N Engl J Med"},{"key":"2539_CR70","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419\u201330.","journal-title":"Lancet."},{"key":"2539_CR71","doi-asserted-by":"publisher","first-page":"154937","DOI":"10.1016\/j.metabol.2021.154937","volume":"127","author":"I Caruso","year":"2022","unstructured":"Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism. 2022;127:154937.","journal-title":"Metabolism."},{"key":"2539_CR72","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019;96:302\u201319.","journal-title":"Kidney Int"},{"issue":"4","key":"2539_CR73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, et al. Selective mineralocorticoid receptor cofactor modulation as ,molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71(4):599\u2013608.","journal-title":"Hypertension."},{"issue":"2","key":"2539_CR74","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152\u201361.","journal-title":"Eur Heart J"},{"key":"2539_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","volume":"29","author":"M Frimodt-M\u00f8ller","year":"2020","unstructured":"Frimodt-M\u00f8ller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2020;29:145\u201351.","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02539-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:28:30Z","timestamp":1701174510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02539-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02539-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"11 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TF provided advisory services to Astra Zeneca, Atrogi, Bayer, Cipla, Eli Lilly, Eysense, Fortbildungskolleg, Novo Nordisk, Pfizer, Sanofi, Remynd, and Roche. TF provided speaker services to Amarin, Astra Zeneca, B\u00f6hringer Ingelheim, Berlin Chemie, Cipla, Daiichi-Sankyo, Eli Lilly, Fortbildungskolleg, MSD, Novartis, Novo Nordisk, Sanofi, and Santis.FG provided advisory services to AstraZeneca, Eli Lilly, Novo Nordisk, Roche Diabetes Care, and Sanofi; received speaker fees and served as a consultant for Boehringer Ingelheim, Lifescan, Merck Sharp & Dohme, Sanofi, AstraZeneca, Medimmune, Roche Diabetes Care, Sanofi, and Medtronic; and received research support from Eli Lilly and Roche Diabetes Care.KRT is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568, and CDC contract 75D301-21-P-12254; other support from Eli Lilly; personal fees and other support from Boehringer Ingelheim; personal fees and other support from AstraZeneca; grants, personal fees, and other support from Bayer AG; grants, personal fees, and other support from Novo Nordisk; grants and other support from Goldfinch Bio; other support from Gilead; and grants from Travere outside the submitted work.RES is supported by grants from AstraZeneca, Boehringer Ingelheim, Lilly, and NovoNordisk to the Institution (University Hospital Eralngen); personal advisory and speaker fees were received from AstraZeneca, Bohringer Ingelheim, and NovoNordisk.NP has been an advisory board member of AstraZeneca, Boehringer Ingelheim, MSD, NovoNordisk, Pfizer, Takeda, and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis, and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, MSD, Mylan, NovoNordisk, Pfizer, Sanofi-Aventis, and Vianex; and attended conferences sponsored by TrigoCare International, Eli Lilly, Galenica, NovoNordisk, Pfizer, and Sanofi-Aventis.DCW has an ongoing consultancy agreement with AstraZeneca. In the last 3 years, he has also received payments from Amgen, Astellas, Bayer, Boehringer Ingelheim, Janssen, Gilead, GlaxoSmithKline, Merck Sharp and Dohme, Mundipharma, Tricida, Vifor, and Zydus.OS is founder and CEO of Sciarc GmbH, Germany.CM serves or has served on the advisory panel for NovoNordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Imcyse, NovoNordisk, Sanofi, and ActoBio Therapeutics; CM serves or has served on the speaker\u2019s bureau for NovoNordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Novartis. Financial compensation for these activities has been received by KU Leuven.AH and MS declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"337"}}